Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer by RUDIN, Charles M, HANN, Christine L, RANSON, Malcolm R, DIVE, Caroline, MCKEEGAN, Evelyn M, CHYLA, Brenda J, DOWELL, Barry L, CHAKRAVARTTY, Arunava, NOLAN, Cathy E, RUDERSDORF, Niki, BUSMAN, Todd A, MABRY, Mack H, GARON, Edward B, KRIVOSHIK, Andrew P, HUMERICKHOUSE, Rod A, SHAPIRO, Geoffrey I, GANDHI, Leena, DE OLIVEIRA, Moacyr Ribeiro, BONOMI, Philip D, ROSS CAMIDGE, D, CHU, Quincy, GIACCONE, Giuseppe, KHAIRA, Divis, RAMALINGAM, Suresh S

Get full text

Abstract A92: A phase 1 safety and pharmacokinetic study of navitoclax in combination with docetaxel in patients with solid tumors by Eskens, Ferry ALM, Gutierrez, Martin, Cosgrove, David, Puglisi, Martina, van Doorn, Leni, Blanco, Montserrat, de Jonge, Maja JA, Moran, Kirsty, Walther, Axel, Yang, Jianning, Busman, Todd A., Franklin, Catherine A., Mabry, Mack H., Humerickhouse, Rod A., Molife, Lulama Rhoda

Get full text

The genotype of the human cancer cell: Implications for risk analysis by Williams, Jerry R., Russell, James, Dicello, John F., Mabry, Mack H.

Get full text

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, ph... by DiNardo, Courtney D, Pratz, Keith W, Letai, Anthony, Jonas, Brian A, Wei, Andrew H, Thirman, Michael, Arellano, Martha, Frattini, Mark G, Kantarjian, Hagop, Popovic, Relja, Chyla, Brenda, Xu, Tu, Dunbar, Martin, Agarwal, Suresh K, Humerickhouse, Rod, Mabry, Mack, Potluri, Jalaja, Konopleva, Marina, Pollyea, Daniel A

Get full text

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia by Wei, Andrew, Strickland, Stephen A., Roboz, Gail J., Hou, Jing-Zhou, Fiedler, Walter, Lin, Tara L., Martinelli, Giovanni, Walter, Roland B., Enjeti, Anoop, Fakouhi, Kaffa, Darden, David E., Dunbar, Martin, Zhu, Ming, Agarwal, Suresh, Salem, Ahmed H., Mabry, Mack, Hayslip, John

Get full text

Second Primary Cancers Related to Smoking and Treatment of Small-Cell Lung Cancer by Tucker, Margaret A., Murray, Nevin, Shaw, Edward G., Ettinger, David S., Mabry, Mack, Huber, Martin H., Feld, Ronald, Shepherd, Frances A., Johnson, David H., Grant, Stefan C., Aisner, Joseph, Johnson, Bruce E.

Get full text

An achaete-scute homologue essential for neuroendocrine differentiation in the lung by Borges, Michael, Linnoila, R. Ilona, van de Velde, Helgi J. K., Chen, Herbert, Nelkin, Barry D., Mabry, Mack, Baylin, Stephen B., Ball, Douglas W.

Get full text

An achaete-scute homologue essential for neuroendocrine differentiation in the lung by Borges, Michael, Linnoila, R. Ilona, van de Velde, Helgi J. K, Chen, Herbert, Nelkin, Barry D, Mabry, Mack, Baylin, Stephen B, Ball, Douglas W

Get full text

A Phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma an eastern cooperative oncology group study by KALEMKERIAN, G. P, JIROUTEK, M, ETTINGER, D. S, DORIGHI, J. A, JOHNSON, D. H, MABRY, M

Get full text

Differential expression of nuclear envelope lamins A and C in human lung cancer cell lines by KAUFMANN, S. H, MABRY, M, JASTI, R, SHAPER, J. H

Get full text

A Phase II study of all‐trans‐retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma by Kalemkerian, Gregory P., Jiroutek, Michael, Ettinger, David S., Dorighi, John A., Johnson, David H., Mabry, Mack

Get full text

Effect of v- rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin by Kaufmann, Scott H., Kalemkerian, Gregory P., Jasti, Rajani, Mabry, Mack

Get full text